Skip to main content
BBIO
NASDAQ Life Sciences

Infigratinib Shows Broad Benefits in Achondroplasia: Sleep Apnea, Ear Infections, and 3-Year Growth Data

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$74.01
Mkt Cap
$14.615B
52W Low
$48.78
52W High
$93.415
52W Position info
52% above low
Off High info
21% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BBIO sits 52% above its 52-week low of $48.78.

Summary

BridgeBio presented new exploratory data from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia at ESPE 2026. The drug stabilized sleep apnea measures (AHI +10.4% vs +49.2% placebo) and reduced ear infections by 38% versus placebo. Three-year data showed sustained growth improvements (height Z-score +0.92 SD) with no new safety signals. The company has submitted an NDA to the FDA and expects a U.S. launch in mid-2027, with an MAA filing to EMA planned for Q4 2026. This broadens the drug's profile beyond the previously reported primary endpoint of annualized height velocity, strengthening its commercial positioning as a potential first oral therapy for achondroplasia.

At the time of this announcement, BBIO was trading at $74.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $76.03 info
Change: +$5.34 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $76.03 info
Change: +$4.59 (+6%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $76.03 info
Change: +$5.36 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $76.03 info
Change: +$10.28 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info